RP72 + gemcitabine

RP72 + gemcitabine is a combination investigational therapy being evaluated for the treatment of pancreatic cancer. RP72 is a novel compound in early-phase clinical trials, while gemcitabine is a nucleoside analog and antimetabolite chemotherapy agent that inhibits DNA synthesis and is widely used as standard therapy for pancreatic and other cancers. The combination is being investigated to determine if RP72 enhances or synergizes with gemcitabine's anti-tumor efficacy. The specific mechanism of action for RP72 is not publicly disclosed, but gemcitabine works by incorporating into DNA during replication, resulting in chain termination and apoptosis of proliferating tumor cells.